Trademark Overview
On Monday, March 22, 2021, a trademark application was filed for NAXIO with the United States Patent and Trademark Office. The USPTO has given the NAXIO trademark a serial number of 90592998. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 27, 2023. This trademark is owned by SOTIO, LLC. The NAXIO trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceutical products for the treatment of cancer or infectious diseases, namely, genetically engineered hematopoietic cells for the treatment of cancer or infectious diseases; pharmaceutical preparations for cell therapy, namely, genetically engineered hematopoietic cells for the treatment of cancer or infectious diseases; biological preparations for cancer therapies and anti-infective therapies, namely, chimeric antigen receptors (CAR) and therapeutic preparations thereof, namely, viral vectors and plasmid vectors expressing CAR genes; therapeutic antibodies for use as immunotherapeutic agents for the treatment of cancer and infectious diseases; therapeutic T-cell receptors for use as immunotherapeutic agents for the treatment of cancer and infectious diseases; preparations for genetically modifying human or animal cells for medical purposes, including viral vectors and plasmid vectors
Medical services, namely, in the extraction of human hematopoietic cells from patients and in genetically modifying hematopoietic cells for therapeutic purposes; Providing medical and therapy advice and consultancy in the field of medical therapies, namely, in the field of genetically engineered hematopoietic cells, cellular therapies, antibody therapies, and T-cell receptor therapies for the treatment of cancer or infectious diseases; providing information regarding the treatment of cancer and infectious diseases by means of a website, namely, in the treatment of cancer and infectious diseases by genetically engineered hematopoietic cells, cellular therapies, antibody therapies, and T-cell receptor therapies
Industrial scientific analysis in the field of pharmaceuticals and biotechnology, namely, in the field of genetically engineered hematopoietic cells, cell therapies, chimeric antigen receptors (CAR), therapeutic antibodies, therapeutic T-cell receptors, viral vectors and plasmid vectors; scientific research services in the field of pharmaceuticals and biotechnology, namely, genetically modifying human or animal cells to enable cells to be used for therapeutic purposes; scientific research in the development of cancer therapies or anti-infective therapies, namely, in the development of genetically engineered hematopoietic cells, cell therapies, chimeric antigen receptors (CAR), therapeutic antibodies, therapeutic T-cell receptors and viral vectors and plasmid vectors
